结构杂交作为一种工具,用于开发新型生物活性类型的protulactone A
Sanja Djokić1, Mirjana Popsavin1, Slađana Stanisavljević1
1University of Novi Sad, Faculty of Sciences, Department of Chemistry, Biochemistry and Environmental Protection, Trg Dositeja Obradovića 3, 21000 Novi Sad, Serbia.
Bioorganic chemistry
|December 23, 2025
概括
新型混合类型的protulactoneA显示强大的抗癌活性对各种癌症细胞系. 选择的化合物调节多种药物耐药性并诱导细胞亡,显示出瘤细胞对正常细胞的高选择性.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症生物学 癌症生物学
背景情况:
- 普罗图拉克A是一种具有潜在生物活性的天然产品.
- 开发具有提高疗效和选择性的新型抗癌药物是一个关键需求.
- 了解结构-活动关系是设计有效治疗方法的关键.
研究的目的:
- 为了合成新型的混合类型的protulactone A.A.的合成.
- 评估这些类型的抗增殖活性与人类癌症细胞系的小组对比.
- 研究它们作为多药耐药性调节剂和亡诱导剂的潜力.
主要方法:
- 综合使用格里格纳德添加,去保护和循环凝结反应的十二种新杂交类型.
- 针对十个瘤细胞系和一个正常细胞系 (MRC-5) 的抗增殖试验.
- 分析多药物耐药性调节,亡诱导 (Caspase-3激活) 和细胞吸收 (LC-MS/MS).
主要成果:
- 几种类型 (9,13,16) 对白血病,乳腺癌和宫癌细胞的IC50值低于10μM.
- 化合物3,8和11降低了MRP1水平,并在K562细胞中诱导了亡.
- 结构-活性关系分析表明,C-7基和特定的立体化学物质可以提高功效.
- 化合物11表现出高吸收和选择性,对正常细胞无毒.
结论:
- 结构性杂交的protulactoneA和 styryl乳是一个可行的策略,开发新的抗癌药物.
- 合成的类似物显示出显著的抗增殖活性和瘤细胞的选择性.
- 这些化合物有望克服多种药物耐药性,并值得进一步研究作为抗癌疗法.
更多相关视频
相关概念视频
Prodrugs
3.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
3.8K
Hybridoma Technology
17.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.1K
Drug Biotransformation: Overview
3.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.5K
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
Structure-Activity Relationships and Drug Design
1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K


